| Table |
|---|
Advertisement
Topics
- Industries
- BioPharmaceutical
- Medical Device
Related Companies
- Warner Chilcott PLC
- Newron Pharmaceuticals SPA
- GlaxoSmithKline PLC
- Affymax Inc.
- Genentech Inc.
- Tanox Inc.
- Novartis AG
- Eli Lilly & Co.
- Icos Corp.
- Gilead Sciences Inc.
- Corus Pharma Inc.
- Myogen Inc.
- Merck & Co. Inc.
- Sirna Therapeutics Inc.
- Johnson & Johnson
- Chattem Inc.
- Pfizer Inc.
- Pfizer Consumer Health Care Group
- Genmab AS
- Bayer AG
- Regeneron Pharmaceuticals Inc.
- Hansen Medical Inc.
- Conor Medsystems LLC
- Biomet Inc.
- DJO Global Inc.
- Kyphon Inc.
- St. Francis Medical Technologies Inc.
- Trividia Health Inc.
- MedCath Corp.
Related Deals
- Warner Chilcott completes $1bn IPO
- CNS drug developer Newron grosses CHF118mm in IPO on SWX
- Affymax completes $99mm IPO
- Genentech buys Tanox for $905mm in cash
- Genentech, Tanox settle anti-1gE antibody suit
- Lilly agrees to buy Icos for $2.1bn
- Gilead acquires remaining Corus shares for $365mm
- Gilead offers $2.2bn for Myogen
- Merck buys Sirna for $1.1bn
- Boehringer Ingelheim buys heartburn drug Zantac for $509.5mm
- Chattem buys J&J, Pfizer OTC drugs for $410mm
- J&J to buy Pfizer Consumer Health Care Group for $16.6bn
- GSK gets late-stage cancer/RA antibody from Genmab; transferred to Novartis
- Bayer gets ex-US rights to anti-VEGF for eye diseases
- Hansen Medical completes $77.9mm IPO
- J&J acquires Conor for $1.26bn
- Private equity group acquires Biomet
- Encore Medical purchased by Blackstone for $870mm
- Kyphon acquires St. Francis for $525mm in cash plus earn-outs
- Kyphon gets spinal device assets from Disc-O-Tech Medical
- Home Diagnostics nets $48.7mm with IPO
- MedCath nets $39.7mm with follow-on public offering
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
IV002894
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
IV002894
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.